Q-omics provides the consensus-scored MIR6747 profile across patient tissues and cancer cell-line models. MIR6747 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR6747 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, MIR6747 RNA expression shows 5,336 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight UVM, STAD, and KIRC as cancer lineages where MIR6747 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6747 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6747 survival associations across molecular data types. MIR6747 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6747 RNA expression–survival associations across cancer types. High MIR6747 expression shows unfavorable associations in UVM, COAD, KIRC, ACC, MESO and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR6747 RNA expression.
This table summarizes MIR6747 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6747. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6747 shows higher tumor expression in STAD, LUSC and LIHC. The STAD box plot shows higher MIR6747 RNA expression in tumor versus normal tissue (log2 FC = +0.378, t-test p = .007).
This table shows molecular features associated with MIR6747 in patient tissues and cancer cell lines. In patient samples, MIR6747 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
